Drug-eluting balloon Bioresorbable vascular scaffold a b s t r a c t
Introduction
The percutaneous coronary intervention (PCI) for treatment of de novo coronary artery disease is well established but the treatment of in-stent restenosis (ISR) in patients with drugeluting stent (DES) is still a major clinical challenge. Various treatment modalities have been used for treatment of ISR ranging from plain old balloon angioplasty (POBA), metallic stent, cutting or scoring balloon to drug-eluting balloon (DEB).
Here, we report a case of DES-ISR treated by using a Bioresorbable Vascular Scaffold (BVS) in patient with unstable angina.
Case report
A 40-year-old hypertensive and non-diabetic female was admitted to our department with gradually progressive angina for last 6 months. She had significant past history of anterior wall myocardial infarction two years prior to admission and underwent PCI to left anterior descending coronary artery (LAD) with sirolimus eluting stent through right transradial approach.12-lead electrocardiogram revealed Q waves with inverted T waves in anterior precordial leads suggesting old anterior wall myocardial infarction. Two-dimensional cross-sectional echocardiographic and Doppler examination revealed severe left ventricle systolic dysfunction (LVEF~30%). In view of crescendo symptoms, after informed consent, coronary angiography was performed via left transradial access using 6 F hydrophilic introducer sheath and 5 F TIG 4.0 catheter, which revealed significant ISR in proximal segment of LAD (Panel A, B Fig. 1 ; S Video 1). Left circumflex coronary (LCX) and right coronary artery (RCA) were non obstructive. PCI of LAD was planned and left coronary ostium was engaged with 6F EBU guide catheter (Launcher, Medtronic, Inc., Minneapolis, MN). The lesion was crossed with 0.009-inch rotawire and rotablation was performed using a 1.5-mm rotaburr (Boston Scientific, Boston, MA, USA) at 1,50,000 rpm (Arrow, Panel C Fig. 1 ; S Video 2). After rotablation, the lesion was crossed with 0.014-inch BMW guidewire (Abbott Vascular, Santa Clara, CA) and rotawire was removed. The lesion was pre-dilated with 2 Â 10 mm Maverick PTCA balloon dilatation catheter (Boston Scientific, Boston, MA, USA) (Arrow, Panel D Fig. 1 
Discussion
The management of patients with ISR is still a major clinical challenge even in era of DES. Although the incidence of ISR is significantly reduced with the use of DES as compared to bare metal stent (BMS) but the absolute number of cases is increased with increase in the complex and multivessel PCI. Moreover, because of diverse etiology of DES-ISR the optimal treatment modality is difficult to determine. 1 The treatment option varies from using vascular brachytherapy (VBT), larger high-pressure balloon dilatation, same or different DES, cutting or scoring balloon and drug-eluting balloon (DEB) but still the optimum treatment strategy is undefined. The VBT is not used now-a-days because of better alternative options and radiation source related logistic issues. 2 The plain old balloon angioplasty (POBA) is mainly limited by frequent slippage of the balloon during inflation and high rate of recurrent restenosis as compared to DES. 3, 4 This problem is overcome by using cutting or scoring balloon but has limitation because of its larger profile which makes it difficult to cross the stented segments especially when the ISR is diffuse. Even in focal ISR, DES is better than cutting balloon in terms of preventing late luminal loss and in preventing recurrent restenosis. 5 Outcomes of same drug DES implantation in focal DES-ISR are excellent although in patients with diffuse DES-ISR, a different drug DES provides better patency. 6 One of the major drawbacks of treatment of ISR with implantation of a stent inside a stent is the metal burden in that segment of the vessel. In large caliber coronary arteries, this strategy is fairly well tolerated, although in smaller caliber vessels where ISR is more likely to occur, metal burden is a limiting issue. DEB is a novel technique of local drug delivery without adding second layer of metal and hence has theoretical advantage over DES but is limited by failure to provide the mechanical scaffolding support to combat acute recoil and to cover dissection flaps. 7 BVS is the latest advance in the armamentarium of interventional therapies for treating de novo significant coronary artery disease. Recent data from trials have suggested many advantages of BVS over DES. 8 The rationale of using BVS in DES-ISR is based on the concept of repeat local drug delivery as achieved by DEB with the benefits of a scaffold to stabilize dissection flaps, and prevent acute recoil as provided by metallic stent, without the permanent bi-layer of metal, that in some vessels, may in and by itself create flow abnormality. 9
Conclusion
This case is the first human experience demonstrating feasibility, and acute efficacy of BVS in a patient with DES-ISR. In view of its appealing biologic advantage, the efficacy and outcomes of a BVS based treatment strategy for DES-ISR need to be evaluated in comparison to other established PCI based therapies, such as repeat DES implantation, in a randomized setting. 
